Form S-8 Sarepta Therapeutics,
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Evercore ISI Upgrades Sarepta Therapeutics (SRPT) to Outperform
August 8, 2024 8:18 AM EDTEvercore ISI analyst Gavin Clark-Gartner upgraded Sarepta Therapeutics (NASDAQ: SRPT) from In Line to Outperform with a price target of $179.00 (from $185.00).
For an analyst ratings summary and ratings history on Sarepta Therapeutics click here. For more ratings news on Sarepta Therapeutics click here.
Shares of Sarepta Therapeutics closed at $140.06 yesterday.
... MoreSarepta Therapeutics (SRPT) PT Lowered to $181 at RBC Capital
August 8, 2024 6:27 AM EDTRBC Capital analyst Brian Abrahams lowered the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $181.00 (from $182.00) while maintaining a Outperform rating.
The analyst comments "SRPT reported 2Q earnings, and we had the chance to follow up with mgmt afterwards. We came away... More
